MAPK3 and neoplasm: MAPK pathway evaluation revealed a marked decrease in the expression level of the phosphorylated form of key pathway-related enzymes, BRAF and ERK1/2 following treatments in comparison to the untreated group, supporting their involvement in tumor growth inhibition.